Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors

Nature Genetics

Volumn 48, Issue 11, 2016, Pages 1330-1338

  Middlebrooks, Candace D ^a   Banday, A Rouf ^a   Matsuda, Konichi ^b   Udquim, Krizia Ivana ^a   Onabajo, Olusegun O ^a   Paquin, Ashley ^a   Figueroa, Jonine D ^c   Zhu, Bin ^a   Koutros, Stella ^a   Kubo, Michiaki ^d   Shuin, Taro ^e   Freedman, Neal D ^a   Kogevinas, Manolis ^f,g,h   Malats, Nuria ⁱ   Chanock, Stephen J ^a   Garcia Closas, Montserrat ^a   Silverman, Debra T ^a   Rothman, Nathaniel ^a   Prokunina Olsson, Ludmila ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

^e KOCHI MEDICAL SCHOOL   (Japan)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

ⁱ Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; ENZYME; ESTROGEN RECEPTOR; UNCLASSIFIED DRUG; APOBEC3A PROTEIN, HUMAN; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; DNA; ISOPROTEIN; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN; SINGLE STRANDED DNA;

AGE; ALLELE; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; ENVIRONMENTAL FACTOR; EUROPEAN; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE CLUSTER; GENE EXPRESSION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GERMLINE MUTATION; HAPLOTYPE; HEREDITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INNATE IMMUNITY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MUTAGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; VIRUS INFECTION; BLADDER TUMOR; BREAST TUMOR; CHROMOSOMAL MAPPING; ENVIRONMENT; GENETIC PREDISPOSITION; GENETICS; MUTATION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMOSOME MAPPING; CYTIDINE DEAMINASE; DNA, NEOPLASM; DNA, SINGLE-STRANDED; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MINOR HISTOCOMPATIBILITY ANTIGENS; MUTAGENESIS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; PROTEINS; RISK ASSESSMENT; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84988431028     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3670     Document Type: Article

References (54)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J. & Stratton, M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
2. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
3. Roberts, S.A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976 (2013).
4. Burns, M.B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366-370 (2013).
5. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
6. Saraconi, G., Severi, F. , Sala, C., Mattiuz, G. & Conticello, S.G. The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol. 15, 417 (2014).
7. Swanton, C., McGranahan, N., Starrett, G.J. & Harris, R.S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704-712 (2015).
8. Chan, K. et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067-1072 (2015).
9. Burns, M.B., Temiz, N.A. & Harris, R.S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977-983 (2013).
10. Rothman, N. et al. A multi-stage genome-wide association study of bladder cancer identifes multiple susceptibility loci. Nat. Genet. 42, 978-984 (2010).
11. Matsuda, K. et al. Genome-wide association study identifed SNP on 15q24 associated with bladder cancer risk in Japanese population. Hum. Mol. Genet. 24, 1177-1184 (2015).
12. Kidd, J.M., Newman, T.L., Tuzun, E., Kaul, R. & Eichler, E.E. Population stratifcation of a common APOBEC gene deletion polymorphism. PLoS Genet. 3, e63 (2007).
13. Caval, V., Suspène, R., Shapira, M., Vartanian, J.P. & Wain-Hobson, S. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B, 3′UTR enhances chromosomal DNA damage. Nat. Commun. 5, 5129 (2014).
14. Qi, G., Xiong, H. & Zhou, C. APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women. Tumour Biol. 35, 5723-5726 (2014).
15. Xuan, D. et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 34, 2240-2243 (2013).
16. Long, J. et al. A common deletion in the APOBEC3 genes and breast cancer risk. J. Natl. Cancer Inst. 105, 573-579 (2013).
17. Nik-Zainal, S. et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 46, 487-491 (2014).
18. Figueroa, J.D. et al. Genome-wide association study identifes multiple loci associated with bladder cancer risk. Hum. Mol. Genet. 23, 1387-1398 (2014).
19. Michailidou, K. et al. Large-scale genotyping identifes 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353-361 (2013).
20. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
21. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
22. Roberts, S.A. & Gordenin, D.A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786-800 (2014).
23. Mifsud, B. et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat. Genet. 47, 598-606 (2015).
24. Göhler, S. et al. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population. J. Cancer Res. Clin. Oncol. 142, 273-276 (2016).
25. Refsland, E.W. et al. Quantitative profling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274-4284 (2010).
26. Land, A.M. et al. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J. Biol. Chem. 288, 17253-17260 (2013).
27. Mussil, B. et al. Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS One 8, e73641 (2013).
28. Akre, M.K. et al. Mutation processes in 293-based clones overexpressing the DNA cytosine deaminase APOBEC3B. PLoS One 11, e0155391 (2016).
29. Sheehy, A.M., Gaddis, N.C., Choi, J.D. & Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
30. Bonvin, M. et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43, 1364-1374 (2006).
31. Wang, Z. et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon β interferon stimulation. J. Virol. 88, 1308-1317 (2014).
32. Strander, H. & Cantell, K. Production of interferon by human leukocytes in vitro. Ann. Med. Exp. Biol. Fenn. 44, 265-273 (1966).
33. Sen, G.C. Viruses and interferons. Annu. Rev. Microbiol. 55, 255-281 (2001).
34. Reid, E. & Charleston, B. Type I and III interferon production in response to RNA viruses. J. Interferon Cytokine Res. 34, 649-658 (2014).
35. Nowarski, R. & Kotler, M. APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion. Cancer Res. 73, 3494-3498 (2013).
36. Dziegielewski, J., Melendy, T. & Beerman, T.A. Bleomycin-induced alterations in DNA replication: relationship to DNA damage. Biochemistry 40, 704-711 (2001).
37. Mullane, S.A. et al. Correlation of APOBEC mRNA expression with overall survival and PD-L1 expression in urothelial carcinoma. Sci. Rep. 6, 27702 (2016).
38. Machiela, M.J., Ho, B.M., Fisher, V.A., Hua, X. & Chanock, S.J. Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. Genome Biol. 16, 193 (2015).
39. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302-308 (2014).
40. Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234-241 (2013).
41. Garcia-Closas, M. et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 73, 2211-2220 (2013).
42. Cescon, D.W., Haibe-Kains, B. & Mak, T.W. APOBEC3B expression in breast cancer refects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl. Acad. Sci. USA 112, 2841-2846 (2015).
43. Vartanian, J.P., Guétard, D., Henry, M. & Wain-Hobson, S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320, 230-233 (2008).
44. Suspène, R. et al. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. USA 102, 8321-8326 (2005).
45. Waters, C.E., Saldivar, J.C., Amin, Z.A., Schrock, M.S. & Huebner, K. FHIT loss-induced DNA damage creates optimal APOBEC substrates: insights into APOBEC-mediated mutagenesis. Oncotarget 6, 3409-3419 (2015).
46. Plimack, E.R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959-967 (2015).
47. Kim, R., Emi, M. & Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1-14 (2007).
48. Rizvi, N.A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
49. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
50. Marx, V. Drilling into big cancer-genome data. Nat. Methods 10, 293-297 (2013).
51. Bullard, J.H., Purdom, E., Hansen, K.D. & Dudoit, S. Evaluation of statistical methods for normalization and differential expression in mRNA-seq experiments. BMC Bioinformatics 11, 94 (2010).
52. Shabalin, A.A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics 28, 1353-1358 (2012).
53. Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633-641 (2013).
54. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39, e118 (2011).